MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ijms26157089

Медицинская библиотека · International journal of molecular sciences · 2025

Development of a Lentiviral Vector for High-Yield Production of Synthetic and Recombinant GCase for Gaucher Disease Therapy.

Coelho Ana Carolina, Wiezel Claudia Emília Vieira, de Campos Alline Cristina, Figueiredo Lílian Louise Souza, Suardi Gabriela Aparecida Marcondes, de Paula Bernardes Juliana, da Cunha Tirapelli Daniela Pretti, Faça Vitor Marcel, Abraham Kuruvilla Joseph, Carlotti-Júnior Carlos Gilberto, Siciliano Velia, Weiss Ron, Gerson Stanton, Fontes Aparecida Maria

СтатьяПеревод в очереди

Аннотация

Gaucher disease (GD) is an autosomal recessive disorder caused by the deficient activity of the lysosomal enzyme glucocerebrosidase (GCase). Although enzyme replacement therapy (ERT) remains the standard of care for non-neuropathic GD patients, its high cost significantly limits accessibility. To enhance production efficiency, we developed a lentiviral system encoding a codon-optimized GCase gene driven by the human elongation factor 1a (hEF1α) promoter for stable production in human cell lines. A functional lentiviral vector, LV_EF1α_GBA_Opt, was generated at a titer of 7.88 × 108 LV particles/mL as determined by qPCR. Six transduction cycles were performed at a multiplicity of infection of 30-50. The transduced heterogeneous human cell population showed GCase-specific activity of 307.5 ± 53.49 nmol/mg protein/h, which represents a 3.21-fold increase compared to wild-type 293FT cells (95.58 ± 16.5 nmol/mg protein/h). Following single-cell cloning, two clones showed specific activity of 763.8 ± 135.1 and 752.0 ± 152.1 nmol/mg/h (clones 15 and 16, respectively). These results show that codon optimization, a lentiviral delivery system, and clonal selection together enable the establishment of stable human cell lines capable of producing high levels of biologically active, synthetic recombinant GCase in vitro. Further studies are warranted for the functional validation in GD patient-derived fibroblasts and animal models.

Для цитирования: Coelho Ana Carolina, Wiezel Claudia Emília Vieira, de Campos Alline Cristina, Figueiredo Lílian Louise Souza, Suardi Gabriela Aparecida Marcondes, de Paula Bernardes Juliana, da Cunha Tirapelli Daniela Pretti, Faça Vitor Marcel, Abraham Kuruvilla Joseph, Carlotti-Júnior Carlos Gilberto, Siciliano Velia, Weiss Ron, Gerson Stanton, Fontes Aparecida Maria. Development of a Lentiviral Vector for High-Yield Production of Synthetic and Recombinant GCase for Gaucher Disease Therapy.. International journal of molecular sciences. 2025. DOI: 10.3390/ijms26157089.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.